⚕ GalenOps CRO console
← SITE014 (NLD)

SITE014-0420

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE014 (NLD) (Dr. Moreau) · consented 2023-08-07
Adverse events
7
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-10-16 (study day 59); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-10-26 (study day 69); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Hyperthyroidism — outcome: RECOVERED/RESOLVED; onset 2023-11-01 (study day 75); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-11-01 (study day 75); relationship: N

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-12-10 (study day 114); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-23 (study day 127); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-01-26 (study day 161); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.